Cyclical Etidronate Therapy for Prevention of Postmenopausal Bone Loss: A 1-Year Open-Label Follow-Up Study

2000 ◽  
Vol 66 (5) ◽  
pp. 348-354 ◽  
Author(s):  
I. Fogelman ◽  
R. J. M. Herd ◽  
G. M. Blake ◽  
R. Balena
Keyword(s):  
Bone Loss ◽  
Postmenopausal Bone Loss ◽  
Open Label ◽  
Follow Up Study ◽  
Cyclical Etidronate

Associations between grip strength change and axial postmenopausal bone loss—a 10-year population-based follow-up study

2005 ◽  
Vol 16 (12) ◽  
pp. 1841-1848 ◽  
Author(s):  
Joonas Sirola ◽  
Marjo Tuppurainen ◽  
Risto Honkanen ◽  
Jukka S. Jurvelin ◽  
Heikki Kröger
Keyword(s):  
Bone Loss ◽  
Grip Strength ◽  
Population Based ◽  
Postmenopausal Bone Loss ◽  
Follow Up Study ◽  
Strength Change

scholarly journals Prevention of Early Postmenopausal Bone Loss with Cyclical Etidronate Therapy (A Double-Blind, Placebo-Controlled Study and 1-Year Follow-Up)*

1997 ◽  
Vol 82 (9) ◽  
pp. 2784-2791
Author(s):  
P. J. Meunier ◽  
E. Confavreux ◽  
I. Tupinon ◽  
C. Hardouin ◽  
P. D. Delmas ◽  
...  
Keyword(s):  
Bone Loss ◽  
Safety Profile ◽  
Treatment Withdrawal ◽  
Controlled Study ◽  
Serum Osteocalcin ◽  
Mineral Density ◽  
Open Label ◽  
Double Blind ◽  
Cyclical Etidronate

Abstract The objective of the study was to evaluate the effects of cyclical therapy with etidronate and calcium on spinal and femoral bone loss in the early post menopausal period. Fifty-four women, 53 ± 2.8 yr old (mean ± sd) and 2.3 ± 1.3 yr post menopause received oral doses of either 400 mg/day etidronate for 2 weeks followed by 500 mg/day elemental calcium for 11 weeks, or placebo for 14 days followed by calcium for 11 weeks, repeated over a total of 24 months. A statistically significant increase in spinal bone mineral density (BMD) was observed after 6 months in the etidronate group. At 2 yr, the mean treatment differences in spinal and femoral neck BMD were+ 2.93% (P < 0.02) and 2.02% (P < 0.03), respectively. Serum osteocalcin and urinary crossLaps/creatinine excretion were decreased signficantly by etidronate. Etidronate was well tolerated with a safety profile similar to that of placebo. Thirty-seven women participated in a 1-yr open-label follow-up study. Twelve months after treatment withdrawal, spinal BMD in the former etidronate group decreased by 1.43% and serum osteocalcin and urinary crossLaps returned to pretreatment values. In conclusion, cyclical etidronate is an effective therapy for the prevention of both trabecular and cortical bone loss in the early menopause and has a good safety profile.

Bone loss in patients with Crohn's disease: A longterm-follow up study

2001 ◽  
Vol 120 (5) ◽  
pp. A628-A628
Author(s):  
P CLEMENS ◽  
V HAWIG ◽  
M MUELLER ◽  
J SCAENZLIN ◽  
B KLUMP ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bone Loss ◽  
Follow Up Study

848 An Open Label Follow-Up Study of Prucalopride Solution in Pediatric Subjects with Functional Fecal Retention

2009 ◽  
Vol 136 (5) ◽  
pp. A-129
Author(s):  
Harland S. Winter ◽  
Jannie Ausma ◽  
Lieve Vandeplassche
Keyword(s):  
Open Label ◽  
Follow Up Study

The relationship of severe health disorders with bone loss, grip strength, and mobility in postmenopausal women – a 15-year follow-up study

2015 ◽  
Vol 38 (14) ◽  
pp. 1407-1414
Author(s):  
Juha Suuronen ◽  
Samu Sjöblom ◽  
Risto Honkanen ◽  
Heli Koivumaa-Honkanen ◽  
Heikki Kröger ◽  
...  
Keyword(s):  
Bone Loss ◽  
Grip Strength ◽  
Postmenopausal Women ◽  
Follow Up Study ◽  
Health Disorders ◽  
Relationship Of ◽  
The Relationship

Prevention of early postmenopausal bone loss by risedronate: One year follow-up data

Bone ◽  
1995 ◽  
Vol 17 (6) ◽  
pp. 607 ◽  
Author(s):  
L. Mortensen ◽  
P. Bekker ◽  
J. DiGennaro ◽  
D. Axelrod ◽  
P. Charles ◽  
...  
Keyword(s):  
Bone Loss ◽  
Postmenopausal Bone Loss ◽  
One Year ◽  
Early Postmenopausal Bone Loss
Sign in / Sign up

Export Citation Format

Share Document